BITTREX-GLOBAL-GMBH
19.4.2022 09:03:08 CEST | Business Wire | Press release
Bittrex Global , a leading digital asset exchange, today welcomes the YellowHeart Protocol, an NFT platform poised to disrupt the ticketing and music industries, to its Initial Exchange Offering (IEO) platform, Bittrex Global Starting Block.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220419005320/en/
By using blockchain technologies, the YellowHeart Protocol is transforming what tickets can do and how they are created, sold and resold. Through the protocol, tickets are now offered as non-fungible tokens (NFTs) and enhanced with new capabilities enabled by the HRTS (pronounced “Hearts”) utility token. In contrast to traditional tickets, NFT tickets offer music, video, and engaging experiences. They enable artists to communicate directly with their fans and provide artists and venues with a share of the proceeds any time a ticket is resold.
The YellowHeart Protocol was created to bring together an entire ecosystem – composed of fans, artists, sports teams, brands, venues, event promoters, and more – to participate in this leap forward. This community comes together at the YellowHeart NFT marketplace, which can be accessed online at yh.io or via the YellowHeart mobile app for iOS and Android.
"In addition to ticket NFTs, the YellowHeart marketplace also offers music NFTs, collectible NFTs and community NFTs. It is already the premier place for musicians to participate in the NFT revolution, where artists like Maroon 5, The Beatles and XXXTentacion are being joined by a rapidly growing community of creators. With the launch of the HRTS token anyone can now join this community; HRTS token holders will be able to engage with each other in innovative ways, creating a decentralized, peer-to-peer platform for ticketing and entertainment. We are proud to be the YellowHeart ecosystem’s founding member and technology provider,” said Josh Katz, founder and CEO of YellowHeart LLC.
“We are pleased to have selected YellowHeart as the first project to be launched on Starting Block. It displays strong signs of promise in the new world of Web 3 ticketing and music, and we are happy to support and generate more awareness around this project through our IEO platform,” said Stephen Stonberg, CEO of Bittrex Global.
“After our team drove an exhaustive, multi-month IEO qualification process, HRTS was selected as the first project to debut on Starting Block for many reasons, including the quality of its token utility value, fully-diluted valuation, circulating supply and demand balance, product roadmap, team experience, brand, and partner accomplishments. We’re excited for the future of the YellowHeart Protocol and think the addition of the HRTS token to the Bittrex Global ecosystem will add significant value for all of our users, especially for those who are lucky enough to get into the IEO,” said Chris Sinkey, Listing Director and Chief Business Officer at Bittrex Global.
Emerging projects looking to IEO can utilize and leverage Bittrex Global’s reputation as one of the most secure digital asset exchanges in the world, committed to using advanced security protocols while remaining compliant with the wide range of regulatory measures across the globe.
The YellowHeart Protocol (HRTS) token sale will launch at 13:00 UTC on May 10, 2022 on Bittrex Global Starting Block.
Learn more: https://global.bittrex.com/Market/Index?MarketName=USDT-HRTS
Disclaimer:
This release is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933. Any public offering of securities to be made in the United States would be made by means of a prospectus that could be obtained from the issuer or selling security holder and that would contain detailed information about the issuer, as well as financial statements. There is no present intention to register any part of the present or proposed offering in the United States.
ABOUT YELLOWHEART PROTOCOL
The YellowHeart Protocol uses blockchain and NFT technologies to disrupt the ticketing industry and transform how artists and fans connect.
YellowHeart LLC is the technology provider and launch partner for the YellowHeart platform. Its marketplace for ticket NFTs, music NFTs, and community tokens attracts premier artists such as the Kings of Leon, Maroon 5, XXXTentacion, Brandi Carlile, ZHU, and more.
ABOUT BITTREX GLOBAL
Bittrex Global, the most secure digital asset exchange in the world, serves both retail and institutional clients, globally. Committed to helping users build wealth, Bittrex Global facilitates the purchase and trade of over 250 tokens. Through its use of cutting-edge technology, advanced security protocols, and a sophisticated elastic multi-stage wallet strategy the company provides a high-level experience for professional and novice customers alike. Bittrex Global is a key player in driving widespread adoption of secure and decentralized methods to building wealth while remaining compliant and adhering to the wide array of regulatory measures across the globe.
Bittrex Global GmbH is registered with the Financial Market Authority under Law of 3 October 2019 on Tokens and TT Service Providers (TVTG) in Liechtenstein to operate as a TT Exchange Service Provider, TT Token Depositary, and Token Issuer on behalf and for the account of third parties. Bittrex Global (Bermuda) Limited is regulated by the Bermuda Monetary Authority and licensed as a Class F Digital Asset Business under the Bermuda Digital Asset Business Act 2018 to operate as a digital asset exchange, provide custodial wallet services, and operate as a digital asset derivative exchange provider.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005320/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom